Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Newly Diagnosed Glioblastoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
      Pathologically confirmed diagnosis of glioblastoma of the cerebrum.
    1. Have a Karnofsky performance status = 70 (i.e., the patient must be able to care for him/herself with occasional help from others).
    2. The result of tumor MGMT methylation study must be available.
    3. The result of tumor IDH-1 mutation test must be available.
    4. Patient must have no active bleeding or pathological condition that carries a high risk of bleeding.

You may not be eligible for this study if the following are true:

    1. Recurrent or progressive glioblastoma.
    2. Gliosarcoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, low grade glioma or any histology other than glioblastoma.
    3. Multicentric glioblastoma or glioblastoma involving the brainstem or cerebellum, or leptomeningeal or spinal extension present at diagnosis.
    4. Residual contrast enhancement > 1 cm3 on post-operative scan obtained within 72 hours of surgery.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.